What is the Historical Analysis of the Plasma Protein Therapeutics Market Size?
The plasma protein therapeutics market has seen considerable growth due to a variety of factors.
• The market size for plasma protein therapeutics has seen significant expansion in the past few years. It's predicted to increase from $31.86 billion in 2024 to $34.55 billion in 2025, showcasing a compound annual growth rate (CAGR) of 8.5%. The historic period's growth can be credited to factors such as the rising incidence of rare diseases, an increase in the aging population, the global availability of blood plasma, a surge in cases of hemophilia, advancements in diagnosis, and a favorable regulatory environment.
What Does Future Hold for The Plasma Protein Therapeutics Market?
The Plasma Protein Therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, a significant increase in the size of the plasma protein therapeutics market is anticipated. It is projected to reach a worth of $46.35 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.6%.
Factors that are largely contributing to this growth during the forecast period include advancements in gene therapy, rise in healthcare spending, adoption of precision medicine tactics, broadened indicators, and patient access programs. The forecast period will also see trends such as the uptake of telemedicine, innovative technological breakthroughs, improvements in plasma fractionation technology, the emergence of next-generation therapies, acceptance of recombinant therapies, and approaches focusing on personalized medicine.
What Are The Primary Growth Drivers In The Plasma Protein Therapeutics Market?
As the occurrence of autoimmune disorders increases, so too is the growth of the plasma protein therapeutics market expected to accelerate. Autoimmune disorders arise when the body's immune mechanisms mistakenly attack and obliterate healthy body cells. Therapeutic plasma exchange is a treatment option for autoimmune illnesses, which occur when the body incorrectly identifies part of itself as alien and generates proteins, referred to as autoantibodies, that strike the misidentified body component. For example, a study conducted by the University of Glasgow, a public university based in the UK, encompassing 22 million individuals in May 2023, determined that around 10% of the UK population is affected by autoimmune disorders, surpassing previous predictions. Therefore, the escalating occurrence of autoimmune disorders is propelling the upward trajectory of the plasma protein therapeutics market.
What Is The Segmentation Of The Global Plasma Protein Therapeutics Market?
The plasma protein therapeutics market covered in this report is segmented –
1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications
Subsegments:
1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
2) By Albumin: Human Serum Albumin, Recombinant Albumin
3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates
4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors
5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates
Pre-Book The Plasma Protein Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Plasma Protein Therapeutics Market Landscape?
The plasma protein therapeutic market is seeing a trend towards product innovation. Major players in this market are focusing on creating innovative solutions to gain a competitive advantage. In October 2023, Octapharma AG, a company based out of Switzerland, received approval from European medical regulators for the lyophilized version of their well-known product, octaplasLG. This new formulation is meant for usage in pre-hospital transfusion, providing a convenient and effective alternative for healthcare experts to handle patients in critical conditions. This approval demonstrates Octapharma's dedication to improving patient care by offering innovative solutions in the blood product sector.
Who Are the Key Players In The Plasma Protein Therapeutics Market?
Major companies operating in the plasma protein therapeutics market include:
• CSL Behring LLC
• Grifols SA
• China Biologic Products Holdings Inc.
• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• Kedrion SpA
• LFB SA
• Emergent BioSolutions Inc.
• Reliance Life Sciences Private Limited
• ADMA Biologics Inc.
• Prothya Biosolutions BV
• Bio Products Laboratory Ltd.
• Biotest AG
• Taibang Biological Group Co Ltd
• Octapharma Plasma Inc.
• New York Blood Center
• Green Cross Corporation
• China National Biotec Group Company Limited
• Kamada Ltd.
• Australian Red Cross Lifeblood
What Are The Regional Insights Into The Plasma Protein Therapeutics Market?
North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
